<DOC>
	<DOCNO>NCT00138541</DOCNO>
	<brief_summary>This 28-week extension study safety effectiveness three dos vildagliptin , unapproved drug , compare placebo lower overall blood glucose level people type 2 diabetes previously treat drug therapy lower blood sugar . The purpose extension study gather long-term safety efficacy data vildagliptin people type 2 diabetes .</brief_summary>
	<brief_title>Extension Study Assess Efficacy Safety Three Doses Vildagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Only patient successfully complete study CLAF237A2301 eligible Written inform consent Ability comply study requirement Premature discontinuation study CLAF237A2301 Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>